This study provides genetic and functional evidence linking breast cancer to meningioma risk through DNA repair and hormonal pathways, supporting early risk assessment and targeted therapies to improve patient outcomes.

1 day ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha)

azacitidine

[Expression of Concern] 5‑Azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene. (PubMed, Oncol Rep)

Owing to the fact that the Editorial Office has been made aware of potential issues surrounding the scientific integrity of this paper, we are issuing an Expression of Concern to notify readers of this potential problem while the Editorial Office continues to investigate this matter further. [Oncology Reports 35: 1375‑1384, 2016; DOI: 10.3892/or.2015.4492].

5 days ago

Journal

DNMT3A (DNA methyltransferase 1) • DNMT3B (DNA Methyltransferase 3 Beta)

azacitidine

Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response. (PubMed, Front Oncol)

The LPMD algorithm effectively captured DNMT3A mutation-associated epigenetic instability (Cohen's d = 0.8, p < 0.001), with the strongest effects observed in the 5'UTR-Exon1 region (d = 0.74) and a gradient pattern from CpG islands to shores (d: 0.59→0.54→0.43). The 5-DMDR panel offers a practical tool for azacitidine response prediction, while dynamic LPMD monitoring provides a potential biomarker for therapeutic guidance. These findings establish methylation disorder as a clinically actionable dimension of epigenetic dysregulation in myeloid malignancies.

5 days ago

Journal

DNMT3A (DNA methyltransferase 1)

azacitidine

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma (clinicaltrials.gov)

P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

5 days ago

Trial completion date

azacitidine • Zolinza (vorinostat)

NCI-2020-14163: Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)

P1/2, N=24, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=44 --> 24

5 days ago

Enrollment closed • Enrollment change

TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SETBP1 (SET Binding Protein 1)

TP53 mutation • NRAS mutation • ASXL1 mutation

azacitidine • seclidemstat (SP2577)

Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) (clinicaltrials.gov)

P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou

5 days ago

New P2 trial

Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=200, Recruiting, Chinese PLA General Hospital | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2026 --> Jan 2029

5 days ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • fludarabine IV • aclarubicin

Azacitidine-induced remission enables allogeneic transplantation in TET2/BCOR-mutant relapsed extranodal natural killer/T-cell lymphoma: a case report. (PubMed, Haematologica)

Not available.

6 days ago

Journal

TET2 (Tet Methylcytosine Dioxygenase 2) • BCOR (BCL6 Corepressor)

TET2 mutation

azacitidine

Treatment of TP53-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax. (PubMed, Haematologica)

Venetoclax (Ven) in combination with hypomethylating agents (HMA) (azacitidine or decitabine) is the standard of care for elderly or unfit patients with acute myeloid leukemia (AML) and is being explored in high-risk myelodysplastic syndrome (HR-MDS). Neutropenic fever occurred in 15%, there were no therapy-related fatalities, and the 100-day mortality was 7.5%. A non-cytotoxic metronomic dosing schedule of decitabine/Ven has a low toxicity profile in TP53-mutated myeloid malignancies.

6 days ago

Journal

TP53 (Tumor protein P53)

TP53 mutation

Venclexta (venetoclax) • azacitidine • decitabine

Medulloblastoma response to mevalonate pathway inhibition is independent of p53 status. (PubMed, Biol Direct)

Silencing p53 also failed to affect simvastatin-induced cell cycle arrest or impact the sensitivity of MB cells treated with simvastatin in combination with hypoxia, X-ray or azacitidine, an epigenetic therapy with DNA methyltransferase inhibition. Collectively, our findings indicate that MVP function is independent of p53 in MB.

6 days ago

Journal

MVP (Major Vault Protein)

TP53 mutation • TP53 wild-type

azacitidine

Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy (clinicaltrials.gov)

P=N/A, N=80, Recruiting, Mayo Clinic | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

6 days ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • azacitidine